|
Dr. Itri is President Pharmaceutical Development and Chief Medical Officer. Previously Dr. Itri was Senior Vice President Worldwide Clinical Affairs and Chief Medical Officer at Ortho Biotech Inc a Johnson & Johnson company. As the senior clinical leader at Ortho Biotech and previously at J&J�s R.W. Johnson Pharmaceutical Research Institute (PRI) she led the clinical teams responsible for NDA approvals for Procrit� (epoetin alpha) that company�s largest single product. She had similar leadership responsibilities for the approvals of Leustatin� Renova� Topamax� Levaquin� and Ultram�. Prior to joining J&J Dr. Itri was associated with Hoffmann-La Roche most recently as Assistant Vice President and Senior Director of Clinical Investigations where she was responsible for all phases of clinical development programs in immunology infectious diseases antivirals AIDS hematology and oncology. Under her leadership in the areas of recombinant proteins cytotoxic drugs and differentiation agents the first successful Product License Application (PLA) for any interferon product Roferon-A� (interferon alfa) was compiled. | 